Parameters | PD-1 | PD-L1 | PD-L2 | ||||||
---|---|---|---|---|---|---|---|---|---|
Positive (n = 18) | Negative (n = 43) | p value | Positive (n = 24) | Negative (n = 37) | p value | Positive (n = 20) | Negative (n = 41) | p value | |
TNBC (n = 61) | |||||||||
Age at operation | |||||||||
≤ 56 | 4 (22.2%) | 24 (55.8%) | 0.016 | 10 (41.7%) | 18 (48.6%) | 0.593 | 12 (60.0%) | 16 (39.0%) | 0.123 |
> 56 | 14 (77.8%) | 19 (44.2%) | 14 (58.3%) | 19 (51.4%) | 8 (40.0%) | 25 (61.0%) | |||
Menopause | |||||||||
Negative | 4 (22.2%) | 18 (41.9%) | 0.121 | 9 (37.5%) | 13 (35.1%) | 0.851 | 8 (40.0%) | 14 (34.1%) | 0.655 |
Positive | 14 (77.8%) | 25 (58.1%) | 15 (62.5%) | 24 (64.9%) | 12 (60.0%) | 27 (65.9%) | |||
Tumor size (cm) | |||||||||
≤ 2 | 3 (16.7%) | 4 (9.3%) | 0.337 | 3 (12.5%) | 4 (10.8%) | 0.573 | 3 (15.0%) | 4 (9.8%) | 0.416 |
> 2 | 15 (83.3%) | 39 (90.7%) | 21 (87.5%) | 33 (89.2%) | 17 (85.0%) | 37 (90.2%) | |||
Lymph node status | |||||||||
Negative | 3 (16.7%) | 8 (18.6%) | 0.586 | 5 (20.8%) | 6 (16.2%) | 0.647 | 3 (15.0%) | 8 (19.5%) | 0.481 |
Positive | 15 (83.3%) | 35 (81.4%) | 19 (79.2%) | 31 (83.8%) | 17 (85.0%) | 33 (80.5%) | |||
Nuclear grade | |||||||||
1, 2 | 13 (72.2%) | 31 (72.1%) | 0.992 | 19 (79.2%) | 25 (67.6%) | 0.324 | 14 (70.0%) | 30 (73.2%) | 0.795 |
3 | 5 (27.8%) | 12 (27.9%) | 5 (20.8%) | 12 (32.4%) | 6 (30.0%) | 11 (26.8%) | |||
Ki67 | |||||||||
≤ 14% | 6 (33.3%) | 12 (27.9%) | 0.672 | 12 (50.0%) | 6 (16.2%) | 0.005 | 6 (30.0%) | 12 (29.3%) | 0.953 |
> 14% | 12 (66.7%) | 31 (72.1%) | 12 (50.0%) | 31 (83.8%) | 14 (70.0%) | 29 (70.7%) | |||
Pathological response | |||||||||
pCR | 3 (16.7%) | 25 (58.1%) | 0.003 | 3 (12.5%) | 25 (67.6%) | < 0.001 | 10 (50.0%) | 18 (43.9%) | 0.654 |
Non-pCR | 15 (83.3%) | 18 (41.9%) | 21 (87.5%) | 12 (32.4%) | 10 (50.0%) | 23 (56.1%) | |||
PD-1 | |||||||||
Negative | Not determined | Not determined | 9 (37.5%) | 34 (91.9%) | < 0.001 | 12 (60.0%) | 31 (75.6%) | 0.210 | |
Positive | 15 (62.5%) | 3 (8.1%) | 8 (40.0%) | 10 (24.4%) | |||||
PD-L1 | |||||||||
Negative | 3 (16.7%) | 34 (48.4%) | < 0.001 | Not determined | Not determined | 10 (50.0%) | 27 (65.9%) | 0.234 | |
Positive | 15 (83.3%) | 9 (51.6%) | 10 (50.0%) | 14 (34.1%) | |||||
PD-L2 | |||||||||
Negative | 10 (55.6%) | 31 (79.1%) | 0.210 | 14 (58.3%) | 27 (73.0%) | 0.234 | Not determined | Not determined | |
Positive | 8 (44.4%) | 12 (20.9%) | 10 (41.7%) | 10 (27.0%) |
Parameters | PD-1 | PD-L1 | PD-L2 | ||||||
---|---|---|---|---|---|---|---|---|---|
Positive (n = 3) | Negative (n = 42) | p value | Positive (n = 4) | Negative (n = 41) | p value | Positive (n = 16) | Negative (n = 29) | p value | |
HER2+BC (n = 45) | |||||||||
Age at operation | |||||||||
≤ 56 | 0 (0.0%) | 20 (47.6%) | 0.162 | 1 (25.0%) | 19 (46.3%) | 0.394 | 6 (37.5%) | 14 (48.3%) | 0.486 |
> 56 | 3 (100.0%) | 22 (52.4%) | 3 (75.0%) | 22 (53.7%) | 10 (62.5%) | 15 (51.7%) | |||
Menopause | |||||||||
Negative | 0 (0.0%) | 18 (42.9%) | 0.206 | 1 (25.0%) | 17 (41.5%) | 0.471 | 6 (37.5%) | 12 (41.4%) | 0.799 |
Positive | 3 (100.0%) | 24 (57.1%) | 3 (75.0%) | 24 (58.5%) | 10 (62.5%) | 17 (58.6%) | |||
Tumor size (cm) | |||||||||
≤ 2 | 1 (33.3%) | 5 (11.9%) | 0.356 | 1 (25.0%) | 5 (12.2%) | 0.448 | 4 (25.0%) | 2 (6.9%) | 0.107 |
> 2 | 2 (66.7%) | 37 (88.1%) | 3 (75.0%) | 36 (87.8%) | 12 (75.0%) | 27 (93.1%) | |||
Lymph node status | |||||||||
Negative | 1 (33.3%) | 15 (35.7%) | 0.715 | 2 (50.0%) | 14 (34.2%) | 0.448 | 5 (31.3%) | 11 (37.9%) | 0.455 |
Positive | 2 (66.7%) | 27 (64.3%) | 2 (50.0%) | 27 (65.8%) | 11 (68.7%) | 18 (62.1%) | |||
Nuclear grade | |||||||||
1, 2 | 2 (66.7%) | 33 (78.6%) | 0.539 | 2 (50.0%) | 33 (80.5%) | 0.209 | 12 (75.0%) | 23 (79.3%) | 0.508 |
3 | 1 (33.3%) | 9 (21.4%) | 2 (50.0%) | 8 (19.5%) | 4 (25.0%) | 6 (20.7%) | |||
Ki67 | |||||||||
≤ 14% | 1 (33.3%) | 23 (54.8%) | 0.449 | 1 (25.0%) | 23 (56.1%) | 0.254 | 7 (43.8%) | 17 (58.6%) | 0.338 |
> 14% | 2 (66.7%) | 19 (45.2%) | 3 (75.0%) | 18 (43.9%) | 9 (56.2%) | 12 (41.4%) | |||
Pathological response | |||||||||
pCR | 0 (0.0%) | 18 (42.9%) | 0.206 | 1 (25.0%) | 17 (41.5%) | 0.471 | 11 (62.5%) | 7 (24.1%) | 0.005 |
Non-pCR | 3 (100.0%) | 24 (57.1%) | 3 (75.0%) | 24 (58.5%) | 5 (37.5%) | 22 (75.9%) | |||
PD-1 | |||||||||
Negative | Not determined | Not determined | 1 (25.0%) | 41 (100.0%) | < 0.001 | 13 (81.3%) | 29 (100.0%) | 0.039 | |
Positive | 3 (75.0%) | 0 (0.0%) | 3 (18.7%) | 0 (0.0%) | |||||
PD-L1 | |||||||||
Negative | 0 (0.0%) | 41 (97.6%) | < 0.001 | Not determined | Not determined | 12 (75.0%) | 29 (100.0%) | 0.012 | |
Positive | 3 (100.0%) | 1 (2.4%) | 4 (25.0%) | 0 (0.0%) | |||||
PD-L2 | |||||||||
Negative | 0 (0.0%) | 29 (69.0%) | 0.039 | 0 (0.0%) | 29 (70.7%) | 0.012 | Not determined | Not determined | |
Positive | 3 (100.0%) | 13 (31.0%) | 4 (100.0%) | 12 (29.3%) |